Katherine A. Hoadley
Born
Shepherdstown, West Virginia, US
Academic background
EducationBA, BS, Chemistry and Biology, 2001, West Virginia Wesleyan College
PhD, 2006, Genetics and Molecular Biology, University of North Carolina at Chapel Hill
ThesisDevelopment of biologically based therapies for basal-like breast tumors (2006)
Academic work
InstitutionsUNC Lineberger Comprehensive Cancer Center

Katherine A. Hoadley is an American breast cancer researcher. As of 2017, she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches.

Early life and education

Hoadley was born and raised in Shepherdstown, West Virginia[1] to a toxicologist father. Her first job was at the United States Department of Agriculture at the age of 16 doing plant research.[2] Hoadley earned her Bachelor of Arts and Bachelor of Science degree from the West Virginia Wesleyan College[2] where she also competed in track and field.[3] She later earned her PhD from the University of North Carolina at Chapel Hill (UNC).[2]

Career

Upon completing her PhD, Hoadley continued to study the complexity of breast cancer as a Research Assistant Professor at UNC.[2] While serving in this role, she worked alongside D. Neil Hayes to document four molecular subtypes of squamous cell cancer for the first time.[4] In 2011, she was the inaugural co-recipient of the new Weatherspoon Family Brain Tumor Research Award for her contributions to the analysis of glioblastomas.[1] The following year, Hoadley co-led a clinical trial testing a combination therapy for basal-like breast cancer which found that a combination of two drugs with promising preclinical results was not as effective as previously believed.[5]

A few years later, Hoadley was a lead researcher at The Cancer Genome Atlas (TCGA) which analyzed over 3,500 tumors across 12 different tissue types to see how they compared to one another. The results of the study found that one in ten cancers analyzed would be classified differently using their new approach.[6] In 2015, she helped identify a group of women with HER2 positive breast cancer who could benefit from less intensive targeted treatment using molecular profiling of patients’ breast cancer tumors. Upon publishing the results, researchers said the findings "could spare unnecessary treatment for those patients and help save health care dollars".[7] Hoadley also found that 51 percent of patients had high expression levels of genes predominately expressed by immune cell subsets.[8]

In 2016, Hoadley co-identified a particular gene expression pattern in normal-appearing breast tissue around tumors that was linked to lower survival rates for women with estrogen receptor-positive breast cancer.[9] As a result of her research, she received a grant from the Susan G. Komen for the Cure organization "to study the genetic and immune cell features of basal-like breast cancer, a poorly understood subtype of breast cancer."[10] The following year, Hoadley was appointed Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility and eventually named an assistant professor in UNC's Department of Genetics.[11]

During the COVID-19 pandemic in North America, Hoadley was the recipient of the Marion R. Wright Award for Scientific Excellence as "an exemplary researcher within the field of metastatic breast cancer within their first three years on faculty."[12] Her work was also listed among the most influential scientific papers on Clarivate’s 2020 Highly Cited Researchers list.[13]

References

  1. 1 2 Hughes, Tom (February 9, 2011). "Carey Anders, Katherine Hoadley are first recipients of new brain tumor research award". healthtalk.unchealthcare.org. Retrieved December 10, 2020.
  2. 1 2 3 4 "Katherine Hoadley: Face of Breast Cancer Researcher". komennctc.org. Retrieved December 10, 2020.
  3. ↑ "GOLDEN EAGLE OPEN TRACK MEET". www.runwv.com. April 14, 2001. Retrieved December 14, 2020.
  4. ↑ "UNC Scientists Confirm Four Molecular Subtypes for Most Common Lung Cancer". unclineberger.org. September 30, 2010. Retrieved December 11, 2020.
  5. ↑ "Combination therapy for triple-negative breast cancer disappointing". unclineberger.org. June 12, 2012. Retrieved December 11, 2020.
  6. ↑ "Largest cancer genetic analysis reveals new way of classifying cancer". unclineberger.org. August 7, 2014. Retrieved December 10, 2020.
  7. ↑ "Subgroup of women with HER-2-positive breast cancer highly sensitive to treatments, study finds". unclineberger.org. November 5, 2015. Retrieved December 10, 2020.
  8. ↑ "UNC Lineberger researchers help map genetic mutations in skin cancer". unclineberger.org. June 18, 2015. Retrieved December 11, 2020.
  9. ↑ "Researchers link gene expression patterns of normal tissue to breast cancer prognosis". unclineberger.org. May 26, 2016. Retrieved December 11, 2020.
  10. ↑ "Breast cancer researchers receive $2.5 million in Susan G. Komen grants". unclineberger.org. September 19, 2016. Retrieved December 11, 2020.
  11. ↑ "Katherine Hoadley, PhD Appointed Assistant Professor in Department of Genetics". med.unc.edu. February 8, 2019. Retrieved December 11, 2020.
  12. ↑ "Breast Cancer Research Foundation honors Hoadley with the Marion R. Wright Award for Scientific Excellence". unclineberger.org. August 31, 2020. Retrieved December 11, 2020.
  13. ↑ "UNC Lineberger faculty among the most highly cited scientists worldwide". unclineberger.org. November 20, 2020. Retrieved December 11, 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.